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COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). Many centers have noticed a high number of venous 
thromboembolism (VTE) events among critically ill inpatients with 
COVID-19 pneumonia. COVID-19 infection is associated with high 
morbidity and mortality largely due to respiratory failure, with micro 
vascular pulmonary thrombosis or PE originating from the leg veins 
playing an additional important pathophysiological role. Having 
undiagnosed or untreated PE may worsen patient outcomes and use of 
empiric therapeutic anticoagulation in certain COVID patients who do not 
have PE/DVT has been advocated. Here, we report a cases of COVID-19, 
in which massive pulmonary thromboembolism (PTE) occurred a few 
days after discharge? 
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Coronavirus disease 2019 (COVID-19) is a 
global pandemic disease caused by the SARS-
COV-2 virus. As of today, healthcare 
practitioners and researchers have made great 
effort to understand the characteristics and 
clinical presentations of the disease. Incubation 
period time is 4 to 5 days and 97.5% of patients 
will exert symptoms within 11.5 days (1) 
Surface spike protein of virus  binding to the 
human angiotensin-converting enzyme 2 
(ACE2) receptor, which is expressed in the lung 
(type 2 alveolar cells), heart, intestinal 
epithelium, vascular endothelium, and kidneys, 
providing a mechanism for multi-organ 
dysfunction. A growing body of evidence 
indicates that coagulopathies and 
thromboembolic events are of utmost 
importance in COVID-19 patients and are 
related to poor prognosis (2). Many centers 
have noticed a high number of venous 
thromboembolism (VTE) events among 
critically ill inpatients with COVID-19 
pneumonia (3). A number of studies have 
shown that coagulation dysfunction exists in 
patients with severe novel coronavirus 
pneumonia (4, 5).  
In one study the incidence of VTE in patients 
with severe NCP (severe novel coronavirus 
pneumonia) is 25% which may be related to 
poor prognosis (6). The significant increase of 
D‐dimer in severe NCP patients is a good index 
for identifying high‐risk groups of VTE (7). 
In this case report, we report a patient with a 
recent hospitalization history of COVID-19 
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who developed symptoms of chest pain after 
discharge which eventually diagnosed 
pulmonary embolism. 
Case report 
A 68-year-old man with a recent hospitalization 
in intensive care unit (ICU) due to covid-19 
infection for 14 days without outpatient 
thromboprophylaxis, present to the emergency 
department of Farschian Heart Center 
(Hamedan, Iran) with symptoms of pleural 
chest pain two days after discharge. He 
mentions chest pain in the right hemithorax 
from yesterday, which gets worse with 
breathing. He reports no cough or dyspnea. Past 
medical and drug history was negative. On 
examination, the patient was a 68 years old 
man, who seemed to be in discomfort. Blood 
pressure on admission was 110/70 mmHg, 
heart rate was 120 beats/minute and the patient 
had a regular body temperature of 37°C and 
SpO2=95% in room air. Auscultation of lung 
revealed no pathologic sound, heart 
auscultation revealed tachycardia and no 
murmur.  
His ECG revealed a sinus tachycardia without 
ST/T changes or axis deviation. In lab tests, 
WBC=14400 (PMN=%75, Lymphocyte=%22), 
Hb=14.4, HCT=57%, Plt=146000, BUN=18, 
Cr=1.3, Na=132, K=3.8, LDH=669, CRP=69, 
ESR=28, CKMB=18, Troponin=Negative, 
BS=157, D-Dimer =4809. The patient was 
admitted and underwent CT pulmonary 
angiography. CT pulmonary angiography 
showed a thrombosis in right lobar and 
segmental branch and left segmental and 
subsegmental branch thrombosis (Figure 1).  
He managed successfully with subcutaneous 
Enoxaparin 1 mg/kg subcutaneous twice daily 
during hospitalization and discharged after 5 
days with Rivaroxaban 15 mg twice daily until 
21 day then 20 mg daily. 
 
Figure 1. CT pulmonary angiography. The arrows 
shows clot in pulmonary artery branches. 
Discussion  
We reported a case of COVID-19 infection who 
did not receive thromboprophylaxis after 
discharge from the hospital. He had been 
referred again and hospitalized with the 
pleuretic chest pain and finally, a pulmonary 
embolism was diagnosed. The association of 
severe COVID-19 with an increased risk of 
venous thromboembolism (VTE) has resulted 
in specific guidelines for its prevention and 
management. The VTE risk appears highest in 
those with critical care admission. The need for 
post discharge thromboprophylaxis remains 
controversial, which is reflected in conflicting 
expert guideline recommendations (8). 
Following discharge, some COVID-19 patients 
may require VTE prophylaxis. A 
multidisciplinary approach involving the 
patient and health care team should be 
implemented (9). Some of the indications for 
outpatient VTE prophylaxis include patients 
who required intensive care unit (ICU) 
management, were mechanically ventilated, 
and were paralyzed for a prolonged period or 
those with VTE risk factors identified on 
discharge (10). In light of increasing evidence 
of a significantly prothrombotic state in patients 
diagnosed with COVID-19 (11,12), Journal of 
the American College of Cardiology (JACC) 
guidance (13), and the American Venous 
Forum white paper (The COVID-19 Sub-
Committee of the American Venous Forum, 
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2020) (13) covering, among other issues, 
inpatient and post discharge 
thromboprophylaxis. In one study 41 out of 119 
patients (34.5%) with confirmed SARS-CoV-2 
infection who had computed tomography 
pulmonary angiogram imaging were diagnosed 
with pulmonary thromboembolism (Barnet 
Hospital, unpublished data, 2020) (14), 
alongside an increasing number of discharged 
patients being readmitted with thrombosis. 
While a number of studies advocate inpatient 
thromboprophylaxis (11), until now, apart from 
these documents (The COVID-19 Sub-
Committee of the American Venous Forum, 
2020) (13), no recommendations have been 
made for discharged patients. The National 
Institute for Health and Care Excellence 
guidance NG89 for venous thromboembolism 
in over 16-year-olds (National Institute for 
Health and Care Excellence, 2018) 
recommends thromboprophylaxis, after risk 
assessment, for acutely ill medical patients for 
at least 7 days. The primary agent of choice is 
low molecular weight heparin with 
fondaparinux as a second choice. A maximum 
duration of anticoagulation was not delineated 
in this group of patients. The time to recovery 
in patients discharged from the hospital setting 
after treatment for SARS-CoV-2 infection is 
often significantly longer than initially might 
have been expected (14). Additionally, these 
patients have been on bed rest and are at risk of 
dehydration for considerable periods during 
their hospital stay, and social distancing while 
both recuperating and rehabilitating will 
dramatically reduce their mobility (7). 
Extrapolating from the National Institute for 
Health and Care Excellence guidance and in 
line with both the JACC guidance (12), and the 
The COVID-19 Sub-Committee of the 
American Venous Forum's (2020) white paper, 
strategy is to initiate chemical 
thromboprophylaxis in risk-assessed patients 
for 2–6 weeks post discharge. As the pandemic 
has impacted on the availability of district 
nurses to attend to patients who cannot self-
treat or receive low molecular weight heparin 
injections from family members, the 
recommendation is that patients are treated with 
a direct oral anticoagulant (10). The primary 
agents of choice are either apixaban 2.5 mg 
twice daily or rivaroxaban 10 mg once daily, 
together with a proton pump inhibitor to reduce 
the risk of clinically relevant non-major 
gastrointestinal bleeding. If a direct oral 
anticoagulant is unsuitable, or if injection of 
low molecular weight heparin is preferred, then 
thromboprophylactic dose low molecular 
weight heparin is advised (14). Where the risk 
of bleeding is significant, mechanical 
thromboprophylaxis with anti-embolism 
stockings is recommended. (13) Thus, extended 
thromboprophylaxis (2–6 weeks) should be 
considered to reduce the risk of venous 
thromboembolism caused by the 
hypercoagulable state and reduced mobility 
during the prolonged convalescent period, after 
a risk assessment is undertaken. Chemical 
thromboprophylaxis with a direct oral 
anticoagulant (such as rivaroxaban or 
apixaban), although outside of licensing, is 
easier to administer than injecting low 
molecular weight heparin in the community 
setting(7). If chemical thromboprophylaxis is 
contraindicated, mechanical 
thromboprophylaxis with anti-embolism 
stockings should be considered (14). 
Conclusions 
Based on the findings, it seems that 
thromboembolic events should be considered as 
a potential cause of clinical deterioration in 
COVID-19 cases and in-charge physicians 
should consider PTE as a differential diagnosis 
for new cardiopulmonary of symptoms in these 
cases during hospital admission and post 
discharge period.  
We believe that thromboprophylaxis after 
discharge in patients with covid-19 infection is 
necessary based on the above report and our 
experience as well as recent studies. 
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